Compare NRK & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRK | OABI |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 815.7M | 696.4M |
| IPO Year | 2002 | 2021 |
| Metric | NRK | OABI |
|---|---|---|
| Price | $9.21 | $4.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.40 |
| AVG Volume (30 Days) | 530.7K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,666,000.00 |
| Revenue This Year | N/A | $87.33 |
| Revenue Next Year | N/A | $24.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.01 | $1.32 |
| 52 Week High | $10.90 | $5.43 |
| Indicator | NRK | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 29.06 | 62.58 |
| Support Level | N/A | $1.90 |
| Resistance Level | $10.67 | $5.43 |
| Average True Range (ATR) | 0.16 | 0.26 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 22.47 | 81.60 |
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.